Special Issue

Application of Artificial Intelligence in Breast Cancer Diagnosis, Prognosis, and Assessing Responses to Treatment

Message from the Guest Editors

Breast cancer continues to present significant challenges due to its multifaceted nature, which is shaped by various factors such as clinical parameters, genetic predispositions, and environmental influences. Despite advancements in screening modalities and therapeutic interventions, early detection remains pivotal in enhancing patients' prognoses. In this regard, the integration of genetic, histological, and imagingbased biomarkers into artificial intelligence (AI) models has shown great potential to enhance breast cancer diagnosis, patient stratification, predictions of responses to treatment, and assessments of early treatment response. We are pleased to invite you to contribute to this Special Issue. We aim to delve into the intricate interplay between different AI models and biomarkers from diverse data sources.

Guest Editors

Dr. Francisco Caramelo

Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Coimbra, Portugal

Dr. Maria João Carvalho

- 1. Coimbra Hospital and Universitary Centre, Gynecology Service, University of Coimbra, Coimbra, Portugal
- Center for Innovative Biomedicine and Biotechnology (CIBB),
 Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra,
 Portugal

Dr. Francisco P. M. Oliveira

Champalimaud Foundation, Lisbon, Portugal

Deadline for manuscript submissions

closed (15 February 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/206262

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

